U.S. Markets closed

Harpoon Therapeutics, Inc. (HARP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.33+0.08 (+0.52%)
At close: 4:00PM EDT

Harpoon Therapeutics, Inc.

131 Oyster Point Boulevard
Suite 300
South San Francisco, CA 94080
United States
650 443 7400

Full Time Employees84

Key Executives

NameTitlePayExercisedYear Born
Dr. Gerald McMahonPres, CEO & Director832.05kN/A1955
Ms. Georgia L. ErbezChief Financial Officer554.55kN/A1967
Dr. Natalie R. SacksChief Medical Offer633.35kN/A1965
Dr. Holger Wesche Ph.D.Chief Scientific OfficerN/AN/A1968
Ms. Rachael LesterVP of Corp. Devel.N/AN/AN/A
Dr. Susan Dana Jones Ph.D.Sr. VP of Product Devel.N/AN/AN/A
Dr. Che-Leung Law Ph.D.Sr. VP of Translational MedicineN/AN/AN/A
Mr. Christopher WhitmoreVP of Fin. & Sec.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Corporate Governance

Harpoon Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.